Xi Jianxin,Chen Yuguo,Geng Xiaochen,et al.Perioperative efficacy study of recombinant humanized anti-CD25 monoclonal antibody combined with steroid minimization for immunoinduction in pediatric liver transplant recipients[J].Journal of Clinical Pediatric Surgery,2025,(03):207-214.[doi:10.3760/cma.j.cn101785-202412054-002]
儿童肝移植受者围手术期CD25人源化单克隆抗体联合激素减量免疫诱导的疗效探讨
- Title:
- Perioperative efficacy study of recombinant humanized anti-CD25 monoclonal antibody combined with steroid minimization for immunoinduction in pediatric liver transplant recipients
- Keywords:
- Liver Transplantation; Recombinant Humanized anti-CD25 Monoclonal Antibody; Acute Rejection; Glucocorticoids; Surgical Procedures; Operative; Child
- 摘要:
- 目的 观察重组抗白细胞分化抗原25(cluster of differentiation 25,CD25)人源化单克隆抗体联合激素减量免疫诱导方案预防儿童肝移植受者急性排斥反应(acute rejection,AR)的效果。方法 回顾性分析2015年7月至2024年8月于吉林大学第一医院接受肝移植的79例儿童受者资料,根据围手术期免疫诱导方案分为全量激素组60例、CD25单抗联合半量激素组19例。全量激素组围手术期采用全量激素诱导,术后采用他克莫司联合激素免疫抑制;CD25单抗联合半量激素组围手术期采用重组抗CD25人源化单克隆抗体联合半量激素诱导,术后单用他克莫司免疫抑制。对比两组术后AR、感染及激素相关并发症等主要结局,以及重症监护室(intensive care unit,ICU)停留时间、移植物存活率、患者存活率、住院时间及住院花费等次要结局的差异。结果 CD25单抗联合半量激素组与全量激素组相比,术后AR发生率(4/19比16/60)、感染发生率(12/19比40/60)、激素相关并发症发生率(11/19比24/60)、排斥反应发生时间差异无统计学意义(P＞0.05),ICU停留时间、住院花费、移植物存活率(18/19比59/60)、患者存活率(19/19比54/60)差异无统计学意义(P＞0.05),但两组住院时间差异有统计学意义(P＜0.05)。结论 重组抗CD25人源化单克隆抗体联合激素减量免疫诱导方案安全有效,能够在减少激素用量的同时实现相似的免疫抑制效果,但与全量激素诱导相比,并不能降低AR、感染及激素相关并发症的发生率。
- Abstract:
- Objective To observe the efficacy of recombinant anti-cluster of differentiation 25 (CD25) humanized monoclonal antibody plus steroid reduction immune induction regimen in preventing acute rejection (AR) in pediatric liver transplant (LT) recipients.Methods Retrospective analysis was conducted for 79 pediatric LT recipients between July 2015 and August 2024.Based upon perioperative immune induction regimens,they were assigned into two groups of full-dose steroid (n=60) and CD25 monoclonal antibody combined with half-dose steroid(n=19).The former group received full-dose steroid induction perioperatively,followed by tacrolimus plus steroids for postoperative immunosuppression.And the latter group received recombinant anti-CD25 humanized monoclonal antibody plus half-dose steroid induction perioperatively,followed by tacrolimus monotherapy for postoperative immunosuppression.The incidence rates of postoperative AR,infection,steroid-related complications and other primary outcomes were compared between two groups.Secondary outcomes,including intensive care unit (ICU) stay,graft survival,patient survival,length of hospitalization stay and hospitalization expenses were also compared.Results The incidence of AR (4/19 vs. 16/60),infection complications (12/19 vs. 40/60) and steroid-related complications (11/19 vs. 24/60) in CD25 monoclonal antibody combined with half-dose steroid group did not significantly differ from full-dose steroid group (P>0.05).Additionally,no significant inter-group differences existed in ICU stay,hospitalization expenses,graft survival rate (18/19 vs. 59/60) or patient survival rate (19/19 vs. 54/60) (P>0.05).However,length of hospitalization stay was significantly shorter in CD25 monoclonal antibody combined with half-dose steroid group than that in full-dose steroid group .Conclusions The recombinant anti-CD25 humanized monoclonal antibody plus steroid reduction immune induction regimen is both safe and effective,achieving similar immunosuppression with tapered steroid dosing.However,as compared with steroid group,it does not significantly lower the incidence of AR,infections or steroid-related complications.
参考文献/References:
[1] 夏强,封明轩.中国儿童肝移植的现状与挑战[J].中华消化外科杂志,2024,23(1):49-54.DOI:10.3760/cma.j.cn115610-20240108-00013. Xia Q,Feng MX.Current status and existing challenges of pediatric liver transplantation in China[J].Chin J Dig Surg,2024,23(1):49-54.DOI:10.3760/cma.j.cn115610-20240108-00013.
[2] Ng VL,Fecteau A,Shepherd R,et al.Outcomes of 5-year survivors of pediatric liver transplantation:report on 461 children from a north American multicenter registry[J].Pediatrics,2008,122(6):e1128-e1135.DOI:10.1542/peds.2008-1363.
[3] Elisofon SA,Magee JC,Ng VL,et al.Society of pediatric liver transplantation:current registry status 2011-2018[J].Pediatr Transplant,2020,24(1):e13605.DOI:10.1111/petr.13605.
[4] Thangarajah D,O’Meara M,Dhawan A.Management of acute rejection in paediatric liver transplantation[J].Paediatr Drugs,2013,15(6):459-471.DOI:10.1007/s40272-013-0034-4.
[5] Jiang YZ,Zhao XY,Zhou GP,et al.Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation:a retrospective cohort study[J].Int J Surg,2023,109(11):3450-3458.DOI:10.1097/JS9.0000000000000631.
[6] 中华医学会器官移植学分会.中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J].中华移植杂志(电子版),2019,13(4):262-268.DOI:10.3877/cma.j.issn.1674-3903.2019.04.002. Branch of Organ Transplantation of Chinese Medical Association.Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J].Chin J Transplant (Electron Ed),2019,13(4):262-268.DOI:10.3877/cma.j.issn.1674-3903.2019.04.002.
[7] Zaydfudim V,Feurer ID,Landman MP,et al.Reduction in corticosteroids is associated with better Health-Related quality of life after liver transplantation[J].J Am CollSurg,2012,214(2):164-173.DOI:10.1016/j.jamcollsurg.2011.10.006.
[8] Gruttadauria S,di Francesco F,Pagano D,et al.Complications in immunosuppressive therapy of liver transplant recipients[J].J Surg Res,2011,168(1):e137-e142.DOI:10.1016/j.jss.2010.09.035.
[9] 段鑫,郑树森.肝移植术后无激素免疫抑制方案研究进展[J].中华移植杂志(电子版),2015,9(2):42-46.DOI:10.3877/cma.j.issn.1674-3903.2015.02.011. Duan X,Zheng SS.Advances in steroid-free immunosuppression after liver transplantation[J].Chin J Transplant (Electron Ed),2015,9(2):42-46.DOI:10.3877/cma.j.issn.1674-3903.2015.02.011.
[10] 董冲,孙超,陈静,等.巴利昔单抗联合减量糖皮质激素诱导免疫方案在儿童肝移植的临床应用[J].中华器官移植杂志,2021,42(3):136-140.DOI:10.3760/cma.j.cn421203-20201213-00421. Dong C,Sun C,Chen J,et al.Clinical observation of basiliximab plus single steroid induced immunotherapy during pediatric liver transplantation[J].Chin J Organ Transplant,2021,42(3):136-140.DOI:10.3760/cma.j.cn421203-20201213-00421.
[11] Rose JW.Anti-CD25 immunotherapy:regulating the regulators[J].SciTransl Med,2012,4(145):145fs25.DOI:10.1126/scitranslmed.3004440.
[12] Arabi F,Mansouri V,Ahmadbeigi N.Gene therapy clinical trials,where do we go?An overview[J].Biomed Pharmacother,2022,153:113324.DOI:10.1016/j.biopha.2022.113324.
[13] Goldschmidt I,Chichelnitskiy E,G?tz J,et al.Early steroids after pediatric liver transplantation protect against T-cell-mediated rejection:results from the ChilSFreestudy[J].Liver Transpl,2024,30(3):288-301.DOI:10.1097/LVT.0000000000000255.
[14] Segev DL,Sozio SM,Shin EJ,et al.Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials[J].Liver Transpl,2008,14(4):512-525.DOI:10.1002/lt.21396.
[15] Becker T,Foltys D,Bilbao I,et al.Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation[J].Transplantation,2008,86(12):1689-1694.DOI:10.1097/TP.0b013e31818fff64.
[16] Otero A,Varo E,de Urbina JO,et al.A prospective randomized open study in liver transplant recipients:daclizumab,mycophenolate mofetil,and tacrolimus versus tacrolimus and steroids[J].Liver Transpl,2009,15(11):1542-1552.DOI:10.1002/lt.21854.
[17] Klintmalm GBG,Washburn WK,Rudich SM,et al.Corticosteroid-free immunosuppression with daclizumab in HCV+liver transplant recipients:1-year interim results of the HCV-3 study[J].Liver Transpl,2007,13(11):1521-1531.DOI:10.1002/lt.21182.
[18] Trune?ka P,Klempnauer J,Bechstein WO,et al.Renal function inde novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study[J].Am J Transplant,2015,15(7):1843-1854.DOI:10.1111/ajt.13182.
[19] Crins ND,R?ver C,Goralczyk AD,et al.Interleukin-2 receptor antagonists for pediatric liver transplant recipients:a systematic review and meta-analysis of controlled studies[J].Pediatr Transplant,2014,18(8):839-850.DOI:10.1111/petr.12362.
[20] Zhang Y,JinW,CaiX.Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients:a systematic review and meta-analysis[J].Ann Med,2017,49(5):365-376.DOI:10.1080/07853890.2016.1257862.
[21] Wang XF,Li JD,Peng Y,et al.Interleukin-2 receptor antagonists in liver transplantation:a meta-analysis of randomized trials[J].Transplant Proc,2010,42(10):4567-4572.DOI:10.1016/j.transproceed.2010.09.169.
[22] Lupo L,Panzera P,Tandoi F,et al.Basiliximab versus steroids in double therapy immunosuppression in liver transplantation:a prospective randomized clinical trial[J].Transplantation,2008,86(7):925-931.DOI:10.1097/TP.0b013e318186b8a3.
[23] Lladó L,Xiol X,Figueras J,et al.Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications:results from a prospective multicenter randomized study[J].J Hepatol,2006,44(4):710-716.DOI:10.1016/j.jhep.2005.12.010.
[24] TeofiliL,Valentini CG,Aceto P,et al.High intraoperative blood product requirements in liver transplantation:risk factors and impact on the outcome[J].Eur Rev Med PharmacolSci,2022,26(1):64-75.DOI:10.26355/eurrev_202201_27749.
[25] Xue MJ,Lv CY,Chen XY,et al.Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation:a retrospective cohort study[J].J Diabetes,2016,8(4):579-587.DOI:10.1111/1753-0407.12356.
[26] Hibi T,Shinoda M,Itano O,et al.Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis[J].Hepatol Res,2015,45(12):1178-1184.DOI:10.1111/hepr.12486.
[27] Calmus Y,Kamar N,Gugenheim J,et al.Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients[J].Transplantation,2010,89(12):1504-1510.DOI:10.1097/TP.0b013e3181db8cf0.
[28] Goralczyk AD,Hauke N,Bari N,et al.Interleukin 2 receptor antagonists for liver transplant recipients:a systematic review and meta-analysis of controlled studies[J].Hepatology,2011,54(2):541-554.DOI:10.1002/hep.24385.
[29] Cillo U,Bechstein WO,Berlakovich G,et al.Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression[J].Transplant Rev,2018,32(3):142-150.DOI:10.1016/j.trre.2018.04.001.
[30] Cantarovich M,Metrakos P,Giannetti N,et al.Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction[J].Transplantation,2002,73(7):1169-1172.DOI:10.1097/00007890-200204150-00030.
[31] Abrahamsson J,Sternby Eilard M,Rizell M,et al.Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation[J].Scand J Gastroenterol,2022,57(3):325-332.DOI:10.1080/00365521.2021.2010799.
[32] Moonka DK,Kim D,Kapke A,et al.The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation[J].Am J Transplant,2010,10(3):590-601.DOI:10.1111/j.1600-6143.2009.02880.x.
[33] Marubashi S,Dono K,Nagano H,et al.Steroid-free living donor liver transplantation in adults:impact on hepatitis C recurrence[J].Clin Transplant,2009,23(6):904-913.DOI:10.1111/j.1399-0012.2009.01022.x.
[34] Hanouneh IA,Zein NN,Lopez R,et al.IL-2 receptor antagonist (Basiliximab) is associated with rapid fibrosis progression in patients with recurrent hepatitis C after liver transplantation using serial biopsy specimens[J].Int J Organ Transplant Med,2010,1(1):7-14.
[35] Vimalesvaran S,Verma A,Dhawan A.Pediatric liver transplantation:selection criteria and post-transplant medical management[J].Indian J Pediatr,2024,91(4):383-390.DOI:10.1007/s12098-023-04963-5.
相似文献/References:
[1]杨振宇,陈福真,李滨,等.小儿亲体部分肝移植治疗肝母细胞瘤(附1例报告)[J].临床小儿外科杂志,2007,6(02):12.
[2]唐艳,刘洋,王紫娟,等. 个体化干预模式在儿童肝移植受者术后随访中的应用[J].临床小儿外科杂志,2016,15(01):41.
[3]余晨,詹江华,高伟,等.胆道闭锁Ｋａｓａｉ术后肝移植患儿不同自体肝生存的临床与病理分析[J].临床小儿外科杂志,2017,16(06):552.
[4]彭宇明,司中州,袁妙贤,等.儿童肝移植20例诊治分析[J].临床小儿外科杂志,2019,18(08):681.[doi:10.3969/j.issn.1671-6353.2019.08.013]
Peng Yuming,Si Zhongzhou,Yuan Miaoxian,et al.Diagnoses and treatments of hepatic transplantation in 20 children[J].Journal of Clinical Pediatric Surgery,2019,18(03):681.[doi:10.3969/j.issn.1671-6353.2019.08.013]
[5]王焕民.开展新技术 提高儿童肝胆肿瘤手术治疗水平[J].临床小儿外科杂志,2020,19(05):377.[doi:10.3969/j.issn.1671-6353.2020.05.001]
Wang Huanmin.Adopting new technology to optimize the surgical treatment of hepatobiliary cancer in children[J].Journal of Clinical Pediatric Surgery,2020,19(03):377.[doi:10.3969/j.issn.1671-6353.2020.05.001]
[6]董岿然.联合肝脏离断和门静脉结扎二步肝切除术在儿童肝肿瘤治疗中的应用[J].临床小儿外科杂志,2020,19(05):382.[doi:10.3969/j.issn.1671-6353.2020.05.002]
Dong Kuiran.Application of associated liver partition and portal vein ligation for staged hepatectomy in the treatment of liver tumors in children[J].Journal of Clinical Pediatric Surgery,2020,19(03):382.[doi:10.3969/j.issn.1671-6353.2020.05.002]
[7]沈秋龙,陈亚军,彭春辉,等.肝脏硬度测量值预测胆道闭锁术后五年自体肝生存的价值研究[J].临床小儿外科杂志,2020,19(06):486.[doi:10.3969/j.issn.1671-6353.2020.06.005]
Shen Qiulong,Chen Yajun,Peng Chunhui,et al.Predicting five-year native liver survival after Kasai procedure of biliary atresia by liver stiffness measurement[J].Journal of Clinical Pediatric Surgery,2020,19(03):486.[doi:10.3969/j.issn.1671-6353.2020.06.005]
[8]隆琦,钭金法,陈菲,等.胆道闭锁Kasai术后自体肝生存良好患儿的营养状况调查[J].临床小儿外科杂志,2020,19(06):491.[doi:10.3969/j.issn.1671-6353.2020.06.006]
Long Qi,Tou Jinfa,Chen Fei,et al.Nutritional status of children with biliary atresia surviving well after Kasai surgery[J].Journal of Clinical Pediatric Surgery,2020,19(03):491.[doi:10.3969/j.issn.1671-6353.2020.06.006]
[9]刘金桥,陈文娟,尹强,等.肝动脉阻力指数对儿童肝移植术后胆道吻合口并发症的预测价值[J].临床小儿外科杂志,2020,19(11):1038.[doi:10.3969/j.issn.1671-6353.2020.11.015]
Liu Jinqiao,Chen Wenjuan,Yin Qiang,et al.Predictive value of hepatic artery resistance index for biliary anastomotic complications after liver transplantation in children[J].Journal of Clinical Pediatric Surgery,2020,19(03):1038.[doi:10.3969/j.issn.1671-6353.2020.11.015]
[10]詹江华,陈亚军.Kasai手术与肝移植治疗胆道闭锁的利弊思考[J].临床小儿外科杂志,2021,20(02):101.[doi:10.12260/lcxewkzz.2021.02.001]
Zhan Jianghua,Chen Yajun.Advantages and disadvantages of Kasai operation and liver transplantation for biliary atresia[J].Journal of Clinical Pediatric Surgery,2021,20(03):101.[doi:10.12260/lcxewkzz.2021.02.001]
备注/Memo
收稿日期:2024-12-19。
基金项目:国家自然科学基金(82241223,U20A20360)
通讯作者:吕国悦,Email:lvgy@jlu.edu.cn